Validating the US pancreas donor risk index in a Norwegian population, a retrospective observational study

Scand J Gastroenterol. 2022 Mar;57(3):345-351. doi: 10.1080/00365521.2021.2012590. Epub 2022 Feb 7.

Abstract

Objectives: Despite advances in immunosuppression and surgical technique, pancreas transplantation is still associated with a significant graft loss rate. The Pancreas Donor Risk Index (PDRI) is a pre-transplant scoring tool derived from a US population. We sought to validate the PDRI in a Norwegian population.

Methods: We retrospectively retrieved donor data for 344 pancreas transplants undertaken in Norway between 2000 and 2019, utilising the Scandiatransplant database, and matched these to the respective recipients. The PDRI score was calculated for each transplanted pancreas, these were then stratified into quintiles. The association between the PDRI quintiles and 1-year graft survival was calculated, and this was repeated for the different types of pancreas transplantation. The association between PDRI as a continuous variable, and graft survival was determined. Donor and recipient data were compared to the original US population.

Results: The overall 1-year graft survival was 82.7%. There were no significant differences in survival between the different PDRI quintiles. When viewed as a continuous variable, increased PDRI score was not associated with decreased graft survival. Significant differences between the Norwegian and US populations were found.

Conclusions: When applied to a Norwegian population, the PDRI score was unable to predict 1-year graft survival.

Keywords: Pancreas transplantation; graft survival; outcome; risk indices.

Publication types

  • Observational Study

MeSH terms

  • Graft Survival
  • Humans
  • Pancreas
  • Pancreas Transplantation* / methods
  • Retrospective Studies
  • Tissue Donors*
  • Treatment Outcome